SecBot SecBot

CELU

Celularity Inc
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001752828 Biotech & Drug Discovery
$0.9457 −0.03 (−3.30%)
Oct 26 4:00 PM ET · prev $0.9780
Market cap
$34.1M
Nano cap
Next earnings
Nov 12
in 17 days
1 year
−54.8%
from $2.09 · Oct 27
30 days
−32.4%
from $1.40
52-week range
$0.5980–2.10
−55% from high · low Jun 30
Avg volume 20D
110.9K
Oct 5 spike 282.0K
Short interest
391.3K
≈1.2% of shares · −52.3%
Days to cover
2.5
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 5 bearish · 0 bullish · 2 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/9 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH The Philip & Daniele Barach Family Trust filed Amendment No. 3 to its Schedule 13D, reporting a significant…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 2 trimmed or exited.

  • Short sellersCOVERING

    Short interest −52.3% to 391.3K shares. 2.5 days to cover, ≈1.2% of shares.

  • TrendDOWNTREND

    28% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.TRIM76,359$45.7K
HRT FINANCIAL LPDOUBLED56,591$33.0K
GROUP ONE TRADING LLCDOUBLED3,595$2.1K
SIMPLEX TRADING, LLCDOUBLED2,188$1.3K
UBS Group AGTRIM1,680$1.0K
MORGAN STANLEYDOUBLED21$13.00
UBS Group AGADD4,529$6.0K
SIMPLEX TRADING, LLCNEAR_EXIT55$73.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Sep 2025
Recent actions
DateFirmActionRating
Sep 9, 2025WBB Securities
UPGRADE
UPGRADEBuy
Aug 18, 2025WBB Securities
INITIATE
INITIATESpeculative Buy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 23, 2026
Philip & Daniele Barach Family Trust
10%+ Owner
OTHER192,771 sh
Sep 23, 2026
Barach Philip Alan
Director
OTHER192,771 sh
Sep 23, 2026
Barach Philip Alan
Director
OTHER2,140,000 sh
Sep 23, 2026
Barach Philip Alan
Director
OTHER1,177,000 sh
Sep 23, 2026
Philip & Daniele Barach Family Trust
10%+ Owner
OTHER2,140,000 sh
Sep 23, 2026
Barach Philip Alan
Director
OTHER1,457,765 sh
Sep 23, 2026
Barach Philip Alan
Director
OTHER1,457,765 sh
Sep 23, 2026
Barach Daniele Wolf
10%+ Owner
OTHER192,771 sh

Earnings setup

Estimates
Nov 12
reports in 17 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
391,276
shares short
-52.3%
vs prior settlement
2.5
days to cover
≈1.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Other
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
Celularity regains Nasdaq reporting compliance and begins a finance department overhaul to strengthe
Oct 20, 2026 SEC
Celularity Inc. filed an Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors…
10-K/A — Impact 5/10
Sep 30, 2026 Press
Celularity highlighted progress at Fontaine Vitale, a regenerative medicine center in Bali, Indonesia, expected to…
Impact 4/10
Sep 29, 2026 SEC
Celularity appointed Naveen Jain (founder/CEO of Viome Life Sciences) to its Board, effective after a Rule 14f-1…
8-K — Impact 4/10
Sep 28, 2026 SEC
The Philip & Daniele Barach Family Trust filed Amendment No. 3 to its Schedule 13D, reporting a significant escalation…
SC 13D/A — Impact 7/10
Sep 23, 2026 Insider
Philip & Daniele Barach Family Trust acquired 192,771 shares
10%+ Owner
Sep 23, 2026 Insider
Barach Philip Alan acquired 192,771 shares
Director
Sep 23, 2026 Insider
Barach Philip Alan acquired 2,140,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
CELU Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 22, 2026
Press release
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
Celularity regains Nasdaq reporting compliance and begins a finance department overhaul to strengthen accountability and ensure timely financial...
Oct 22, 2026
Listing
Listing Status: CELU — Normal (was Delinquent)
Celularity Inc. - Class A Common Stock | Nasdaq Financial Status Indicator E → N
Sep 30, 2026
Contract
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative…
Sep 24, 2026
Earnings
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
Celularity closes $10 million financing in an up to $28 million recapitalization, advancing growth and targeting positive operating cash flow by Q1…
Sep 11, 2026
Listing
Listing Status: CELU — Delinquent (was Deficient & Delinquent)
Celularity Inc. - Class A Common Stock | Nasdaq Financial Status Indicator H → E

SecBot reports

10 filings · 5 press releases · 0 bullish · 6 bearish · 2 mixed · 2 neutral
All CELU filing & press-release reports (15)